Clinical trials: Light-Chain Amyloidosis
AL Amyloidosis
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
This will be a systematic, combined, prospective assessment of the novel echographic, CMR, and PET imaging tools in newly-diagnosed patients with cardiac AL amyloidosis at baseline and after treatment.
- Trial name
- NCT04392960
- Testing
- [18F]Florbetaben
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Systemic Amyloidosis, PET/MR
The Diagnostic Value of Hybrid PET/MR for Systemic Amyloidosis
Systemic amyloidosis is a multi-system disease caused by extracellular deposition of insoluble amyloid fibrils in various tissues and organs, leading to progressive organ dysfunction.
- Trial name
- NCT04006223
- Testing
- 11C-PIB or 18F-florbetapir PET/MR before biopsy and treatment, 11C-PIB or 18F-florbetapir PET/MR after treatment
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Amyloid Light-chain Amyloidosis
Teclistamab-Daratumumab in AL Amyloidosis
The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis. The study treatment is divided into cycles (C) and each cycle is 28 days (D).
- Trial name
- NCT07110844
- Testing
- Teclistamab, Daratumumab and Hyaluronidase-fihj
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Rajshekhar Chakraborty, MD
Amyloidosis
Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis
Amyloidosis results from tissue deposition of amyloid protein, composed mainly by the fragments of monoclonal immunoglobulin heavy chains or light chains.
- Trial name
- NCT00621400
- Testing
- Lenalidomide, Melphalan, Dexamethasone
- Where
- 12 sites in France
- Volunteers
- 27 people
- Sponsor
- Nantes University Hospital
Primary Systemic Amyloidosis
Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis
Iododoxorubicin may dissolve protein deposits and be an effective treatment for primary systemic amyloidosis. Phase I trial to determine the effectiveness of iododoxorubicin in treating patients who have primary systemic…
- Trial name
- NCT00030381
- Testing
- 4'-iodo-4'-deoxydoxorubicin, pharmacological study
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Primary Amyloidosis
Radioimmunoimaging of AL Amyloidosis
The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive monoclonal antibody to document the presence and distribution of amyloid deposits by PET/CT imaging in patients with AL amyloidosis.
- Trial name
- NCT00807872
- Testing
- 124I-labeled monoclonal antibody Mu 11-1F4
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Tennessee
Multiple Myeloma, Plasma Cell Neoplasm
Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction
RATIONALE: Antibodies, such as human immune globulin, can block the growth of abnormal cells in different ways. Some block the ability of abnormal cells to grow and spread.
- Trial name
- NCT00547365
- Testing
- Human immune globulin intravenous (IGIV)
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Tennessee
AL Amyloidosis
A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement
This is an exploratory study to assess the binding of CAEL-101/anselamimab to amyloid in vivo, recruitment of inflammatory cells and reduction of the amyloid mass.
- Trial name
- NCT07615270
- Testing
- Anselamimab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Stanford University
AL Amyloidosis
Radioimmunoimaging of Light Chain (AL) Amyloidosis
The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive monoclonal antibody (mAb) to document the presence and distribution of amyloid deposits by PET/CT imaging in patients with AL amyloidosis.
- Trial name
- NCT01815086
- Testing
- Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Tennessee
Myeloma Multiple, Plasma Cell Leukemia
The Norwegian Immunotherapy in Multiple Myeloma Study
The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in Norway.
- Conditions
- Myeloma Multiple, Plasma Cell Leukemia, AL Amyloidosis
- Trial name
- NIMMS (NCT06855121)
- Testing
- Teclistamab, Elranatamab, Ciltacabtagene Autoleucel
- Where
- 23 sites in Norway
- Volunteers
- 400 people
- Sponsor
- St. Olavs Hospital
Primary Systemic (AL) Amyloidosis
The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis
This is a multi-center, international, randomized, double-blind, placebo-controlled, two-arm efficacy and safety study in subjects newly diagnosed with AL amyloidosis.
- Trial name
- VITAL (NCT02312206)
- Testing
- NEOD001
- Where
- 79 sites in United States, Australia and 13 more
- Volunteers
- 260 people
- Sponsor
- Prothena Biosciences Ltd.
Plasma Cell Dyscrasia, Monoclonal Gammopathy
A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early
This protocol seeks to enroll smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significant (MGUS) patients with λ light chain (LC) involvement, a group of patients for whom standard of care is…
- Trial name
- SAVE (NCT02741999)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Tufts Medical Center
AL Amyloidosis
A Trial for Systemic Light-chain (AL) Amyloidosis
In this multi-center phase III trial, untreated patients diagnosed with AL who are not candidates for stem cell transplant with melphalan 200 mg/m2 are the target population. Stage I and II patients will be eligible.
- Trial name
- EMN-03 (NCT01277016)
- Testing
- BMDex
- Where
- Italy
- Volunteers
- 110 people
- Sponsor
- European Myeloma Network B.V.
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00004904
- Testing
- anti-thymocyte globulin, filgrastim, cladribine
- Where
- United States
- Sponsor
- Northwestern University
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer
This clinical trial studies massage therapy given by caregiver in treating quality of life of young patients undergoing treatment for cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Trial name
- NCT01053494
- Testing
- massage therapy, questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Wake Forest University Health Sciences
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003406
- Testing
- carboplatin, docetaxel, ifosfamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cancer Treatment Centers of America
Primary Systemic Amyloidosis (AL)
Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis
AL amyloidosis is caused by a clonal plasma cell dyscrasia and characterized by progressive deposition of amyloid fibrils derived from monoclonal Ig light chains, leading to multisystem organ failure and death.
- Trial name
- NCT00344526
- Testing
- Melphalan, Dexamethasone, Autologous stem cell transplantation
- Where
- 8 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Limoges
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms
Evaluation of Skin Tests in Biotherapy Allergies
Biotherapies are biological (extracted from an organism or living tissue) or biotechnological drugs used in the treatment of multiple conditions, such as autoimmune inflammatory diseases, cancers, and hematologic diseases.
- Conditions
- Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms, Small Cell Bronchial Carcinomas, Bronchial Carcinoma
- Trial name
- ETCABIO (NCT06971848)
- Testing
- Drug skin tests (investigating hypersensitivity to a biotherapy)
- Where
- France
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
AL Amyloidosis
Daratumumab for the Treatment of Patients With AL Amyloidosis
Participants with AL Amyloidosis will receive the drug daratumumab by IV infusion once weekly for two months, then every 2 weeks for four months, then once each month.
- Trial name
- NCT02841033
- Testing
- daratumumab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Boston Medical Center
AL Amyloidosis
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down.
- Trial name
- NCT04512235
- Testing
- CAEL-101, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen
- Where
- 110 sites in United States, Australia and 17 more
- Volunteers
- 281 people
- Sponsor
- Alexion Pharmaceuticals, Inc.